Trending Up0.0100 (0.4785%)
  • Bid / Lots
    2.0800/ 5
  • Ask / Lots
    2.1000/ 5
  • Open / Previous Close
    2.0900 / 2.0900
  • Day Range
    Low 2.0532
    High 2.1150
  • 52 Week Range
    Low 1.8800
    High 8.1600
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.09
09:32 ET23942.09
09:33 ET6192.0746
09:37 ET1002.115
09:39 ET5052.0532
09:42 ET6002.0685
09:44 ET9002.0783
09:50 ET2002.0775
09:55 ET20002.0899
09:57 ET3502.08
10:00 ET3222.0605
10:02 ET1002.08
10:08 ET1002.08
10:11 ET1002.09
10:15 ET1002.08
10:18 ET1002.07
10:22 ET1502.07
10:24 ET1002.07
10:40 ET1002.08
11:14 ET5002.0615
11:20 ET5502.0884
11:21 ET12992.08
11:23 ET2002.07
11:30 ET1002.08
11:39 ET1002.0693
11:41 ET7002.08
11:48 ET1002.1
11:50 ET1002.08
11:52 ET3002.0898
11:56 ET1002.085
11:57 ET33012.09
11:59 ET20002.095
12:01 ET22832.09
12:03 ET10002.09
12:06 ET8902.07
12:12 ET12002.08
12:15 ET1002.0777
12:24 ET5002.08
12:26 ET1002.1
12:28 ET10002.0804
12:30 ET1002.1
12:32 ET1002.1
12:35 ET21002.0891
12:37 ET2002.1
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMYMD
MyMD Pharmaceuticals Inc
United StatesIMUN
Immune Therapeutics Inc
United StatesNRXP
NRX Pharmaceuticals Inc
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
United StatesDBTX
Decibel Therapeutics Inc
United StatesENLV
Enlivex Therapeutics Ltd
As of 2022-11-29

Company Information

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.

Contact Information

855 N. WOLFE STREET, SUITE 623BALTIMORE, MD, United States 21205


Independent Chairman of the Board
Joshua Silverman
President, Director, Chief Medical Officer
Chris Chapman
Interim Chief Financial Officer
Ian Rhodes
Executive Vice President of Operations, General Counsel
Paul Rivard
Chief Scientific Officer
Adam Kaplin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.